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Pain is one of the most pervasive symptoms in clinical medicine; 
it occurs in a multitude of clinical conditions and is encountered 
by clinicians in every subspecialty. Yet treatment of chronic or 
recurrent pain remains challenging, in part because the thera-
peutic armamentarium is incomplete. Hopefully, this will change 
as a result of increased understanding of the molecular basis of 
pain. Over the past several years, elucidation of the genetic defects 
underlying three monogenic pain disorders has provided impor-
tant insights about human pain and its molecular substrates. 
Here, we briefly review these recent advances.
A genetic basis for pain
The unraveling of the human genome may allow us to compare 
variations at the genetic level with interindividual differences in 
pain thresholds and pain perception. Most studies in the past have 
focused on genetic polymorphisms that might be responsible for 
interindividual differences  in pain perception. For example, a 
common functional SNP (V58M) in the catechol-O-methyltransfer-
ase (COMT) gene modifies pain sensitivity (1). COMT has broad 
biological functions, including the metabolism of catecholamines, 
such as neurotransmitters, that modulate neuronal cell signaling. 
Individuals homozygous for the Val genotype are less sensitive to 
pain compared with those with Met homozygosity (1); however, 
the differences in pain sensitivity between groups are relatively 
subtle. A more dramatic set of observations has been reported in 
studies of rare Mendelian disorders. Over a decade ago, mutations 
in the voltage-dependent calcium channel, P/Q type 1A α subunit 
(CACNL1A4) were identified in families with familial hemiplegic 
migraine, a subtype of migraine with aura and paralysis (2). This 
finding indicated that channel dysfunction could lead to human 
disorders in which pain is a prominent symptom. More recent 
genetic studies have identified the voltage-gated sodium-channel 
type IX α subunit (SCN9A, referred to herein as Nav1.7) as a key 
player in three conditions in which recurrent pain or the inabil-
ity to sense pain is a prominent symptom (3–8). These disorders 
— primary erythermalgia (PE), paroxysmal extreme pain disorder 
(PEPD), and channelopathy-associated insensitivity to pain (CIP) 
— are typified by very different pain phenotypes. Remarkably, 
recent work has shown that different types of channelopathies 
(diseases caused by disturbed function of ion channel subunits 
or the proteins that regulate them), all involving the same Nav1.7 
sodium channel, underlie all three of these disorders (3–8). These 
discoveries allow better understanding not only of the molecular 
pathogenesis of these particular disorders but also of the molecu-
lar pathophysiology of pain (9).
Sodium channels
Voltage-gated sodium channels play a critical role in the generation 
and conduction of action potentials and are thus important for 
electrical signaling by most excitable cells (10, 11). Sodium chan-
nels are integral membrane proteins and are comprised of a large α 
subunit, which forms the voltage-sensitive and ion-selective pore, 
and smaller auxiliary β subunit(s) that can modulate the kinetics 
and voltage dependence of channel gating (12). To date, we know 
of 9 isoforms of the sodium-channel α subunit (Nav1.1–Nav1.9), 
each with a unique central and peripheral nervous system distribu-
tion (10). Four closely related sodium channels (Nav1.1, -1.2, -1.3, 
and -1.7) are encoded by a set of 4 genes (SCN1A, SCN2A, SCN3A, 
and SCN9A, respectively) located within a cluster on chromosome 
2q24.3. Mutations in the genes encoding Nav1.1, -1.2, and -1.3 are 
responsible for a group of epilepsy syndromes with overlapping 
clinical characteristics but divergent clinical severity (13, 14). Here, 
we focus on one of the α subunits, Nav1.7, because of its critical 
role in pain sensation.
Nav1.7 is encoded by SCN9A, a 113.5-kb gene comprising 26 exons 
(OMIM 603415) (Figure 1A). The encoded sodium channel is com-
posed of 1977 amino acids organized into 4 domains, each with 6 
transmembrane segments (15), and is predominantly expressed in 
the dorsal root ganglion (DRG) neurons and sympathetic gangli-
on neurons (16) (Figure 1B). Immunohistochemical studies show 
that Nav1.7 is present at the distal ends of the wire-like projections 
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of neurons known as neurites, close to the impulse trigger zone 
where neuronal firing is initiated (16) (Figure 2). Interestingly, the 
large majority of DRG neurons that express Nav1.7 are pain sens-
ing (nociceptive), suggesting a role for this sodium channel in the 
pathogenesis of pain (17). In addition to Nav1.7, Nav1.8 and Nav1.9 
are also predominantly present in small nociceptive sensory neu-
rons and the nerve fibers emanating from them (18, 19).
Physiology of Nav1.7
In sensory neurons, multiple voltage-dependent sodium currents 
can be differentiated by their gating kinetics and voltage depen-
dence and can also be defined by their sensitivity to the voltage-
gated sodium-channel blocker tetrodotoxin (12). The Nav1.7 chan-
nel produces a rapidly activating and inactivating current that is 
sensitive to submicromolar levels of tetrodotoxin. This is in con-
trast with Nav1.8, which is also present within DRG neurons but 
is fairly resistant to tetrodotoxin. Nav1.7 appears to be important 
in early phases of neuronal electrogenesis. Nav1.7 is characterized 
by slow transition of the channel into an inactive state when it is 
depolarized, even to a minor degree, a property that allows these 
channels to remain available for activation with small or slowly 
developing depolarizations, usually mimicked by electrophysiolo-
gists as ramp-like stimuli (20). Thus, Nav1.7 acts as a “threshold 
channel” that amplifies small, subtle depolarizations such as gen-
erator potentials, thereby bringing neurons to voltages that stimu-
late Nav1.8, which has a more depolarized activation threshold and 
Figure 1
Mutations in the sodium-channel subunit Nav1.7 that are associated with the genetic pain disorders PE, PEPD, and CIP. (A) Nav1.7 is encoded by 
the 113.5-kb gene SCN9A, comprising 26 coding exons. The identity and location of known patient mutations in Nav1.7 that have been linked to 
PE (*), PEPD (^), and CIP (#) are shown. Note that the mutations are spread over the entire gene sequence; however, mutations linked to PEPD 
tend to be located closer to the 3′ end of the gene. (B) A schematic of the Nav1.7 sodium-channel subunit showing the 4 domains (D1–D4), each 
with 6 transmembrane segments. Locations of known mutations associated with genetic pain disorders PE, PEPD, and CIP are shown. COOH 
indicates the C-terminus of the peptide chain. HN indicates the N-terminus of the peptide chain.
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which produces most of the transmembrane current responsible 
for the depolarizing phase of action potentials (21). In this regard, 
Nav1.7 is poised as a molecular gatekeeper of pain detection at 
peripheral nociceptors.
Inflammatory mediators and pain
A number of (inflammatory) mediators, such as prostaglandin 
(22), adenosine (23), and serotonin (24), affect the electrophysio-
logical properties of voltage-gated sodium channels. These media-
tors increase the magnitude of the current, lead to activation of the 
channel at more hyperpolarized potentials, and enhance the rates 
of channel activation and inactivation. As a consequence, inflam-
mation can sensitize nociceptive neurons. In an experimental 
model of inflammatory pain in which an irritant was injected into 
the hind paw in rats, Nav1.7 protein expression was upregulated 
within DRG neurons that project their axons to the inflamed area 
(25), a change that should increase excitability of these cells. Col-
lectively, these data suggest that Nav1.7 contributes, at least in 
part, to pain associated with inflammation.
Animal studies of Nav1.7
To obtain insight into the physiological role of Nav1.7, Nassar et al. 
generated targeted knockout mice that lack Nav1.7 within noci-
ceptive DRG neurons (26). Selective deletion of Nav1.7 in nocicep-
tors from mice produces a phenotype in which heat-induced pain 
thresholds are minimally altered, there is no change in punctate 
mechanical pain threshold, and cold-evoked channel activity is 
unchanged. In contrast, there is a general failure to develop pain or 
hypersensitivity in response to inflammatory stimuli, while neu-
ropathic pain (chronic pain resulting from injury to the nervous 
system) remains intact. These results are consistent with an impor-
tant role of Nav1.7 in setting the inflammatory pain threshold. 
To assess the role of Nav1.7 further, especially in relation to other 
sodium channels expressed in peripheral sensory neurons, the 
same researchers created mice deficient in both Nav1.7 and Nav1.8 
(27). Mice deficient in Nav1.8 had deficits in sensing inflamma-
tory pain (initiated by tissue damage/inflammation) and visceral 
pain (initiated by damage or injury to internal organs) but not 
neuropathic pain (28). The thermal pain threshold in mice defi-
cient in both Nav1.7 and Nav1.8 mice was twice that of mice lack-
ing only Nav1.7. There was no effect on induced neuropathic pain 
in the double knockouts, and the effect of the loss of Nav1.7 in 
raising the threshold for inflammatory pain was so overwhelm-
ing that no additional effect of Nav1.8 deletion was seen. Collec-
tively, these results clearly implicate Nav1.7 as a major sodium 
channel in peripheral nociception and suggest a functional link 
to Nav1.8. Although insightful, these data should be interpreted 
with caution, as direct evaluation of pain in mice is not possible. 
Instead, researchers rely on behavioral changes of animals such 
as signs of paw guarding, lifting, and limping. As a consequence, 
the relevance of the observed changes to human pain remains 
to be determined.
Primary erythermalgia
Primary or idiopathic erythermalgia (OMIM 133020) is an autoso-
mal dominant, inherited disorder. Clinically, PE is characterized by 
attacks or episodes of symmetrical burning pain of the feet, lower 
legs, and sometimes hands, elevated skin temperature of affected 
areas, and reddened extremities (Figure 3) (29–32). PE is sometimes 
termed erythromelalgia, although some authorities reserve the latter 
term for a condition that is caused by arteriolar inflammation as a 
result of platelet-rich thrombi in the end-arterial microvasculature, 
in which the platelet count is invariably elevated (> 400 × 109 cells/l) 
and a short course of aspirin brings swift relief (33). Platelet counts 
in PE are invariably normal, and aspirin is ineffective. Patients 
with PE usually develop symptoms within the first decade of life. 
As the disease progresses, the erythema can extend to the upper 
legs, nose tip, earlobes, and chin. In the early years of the disease, 
the erythema is intermittent, but at later ages, the feet and hands 
may be constantly red and edematous. Complaints are provoked by 
Figure 2
Neuronal Nav1.7 channels. Nav1.7 (shown here in red after immuno-
cytostaining with anti-Nav1.7 antibody; Alomone Reagents) within the 
tip of a growing neurite from rat DRG neuron in culture. Image kindly 
provided by Joel A. Black, Department of Neurology, Yale University, 
New Haven, Connecticut, USA.
Figure 3
Red feet and lower legs in a patient with primary erythermalgia. Image 
courtesy of The Erythromelalgia Association.
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exercise, prolonged standing, or exposure to warmth, which usually 
compels patients not to wear socks or closed shoes, even during the 
winter. Patients typically sleep with uncovered feet, often cooled by 
a fan. Cold alleviates these complaints, and some patients search 
for relief by immersion of feet in ice-cold water. The greatest threat 
is that these actions can lead to trench foot with subsequent skin 
infections and even to limb amputations (34).
A genome-wide linkage study in a large kindred of individuals 
with PE detected strong evidence for linkage with polymorphic 
markers on chromosome 2q  (35). Haplotype analysis  in  four 
additional families confirmed the locus, and recombinant events 
defined the critical interval to 7.94 cM. Subsequent analysis of 
another family allowed narrowing of the region to 5.98 cM (3). 
This  interval contains five genes encoding sodium-channel α 
subunits. After confirming the presence of this genetic interval in 
two affected families, two candidate genes, including SCN9A, were 
tested (3). A missense mutation (L858H) in SCN9A was identified 
that segregated with the disease in a three-generation Chinese fam-
ily while an I848T mutation was present in a single sporadic case. 
Both mutations affected conserved residues in the pore-forming α 
subunit of the Nav1.7 channel, and multiple alignment indicated 
that the affected amino acids are conserved in sodium channels. 
Subsequent independent studies confirmed these findings and 
identified missense mutations (mutations in which one amino 
acid is replaced by another) in individuals from all of the families 
that had been examined in the original linkage study (4). To date, 
nearly a dozen SCN9A mutations in multiple families have been 
identified as causing PE (5, 6, 36–41). Most of these mutations 
have been found in families from The Netherlands, the United 
States, Belgium, France, Canada, and China, with a clear autoso-
mal dominant inheritance pattern, although a few represent de 
novo founder mutations (a mutation that arose in the DNA of an 
individual several generations earlier and whom is considered to 
be a founder of a distinct population) (5, 6).
All of the PE mutations detected to date are missense mutations 
that change important and highly conserved amino acid residues 
of the Nav1.7 protein. The majority of mutations that cause PE 
are located in cytoplasmic linkers of the Nav1.7 channel, but some 
mutations (e.g., F216S and N395K) are located in transmembrane 
domains of the channel (Figure 1B). The PE mutations cause a 
hyperpolarizing shift in the voltage dependence of channel acti-
vation, which allows the channel to be activated by smaller than 
normal depolarizations, thereby likely enhancing the activity of 
Nav1.7. Most of the PE mutations also slow deactivation, thus 
keeping the channel open longer once it is activated (Figure 4). 
In addition, in response to a slow, depolarizing stimulus, most 
mutant channels will generate a larger than normal inward sodi-
um current. Repriming, which is the recovery from inactivation, 
has been shown to be faster for channels possessing specific PE 
mutations (5, 6, 36, 38, 39, 42, 43). Each of these alterations in 
activation and deactivation can contribute to the hyperexcitability 
of pain-signaling DRG neurons expressing these mutant channels, 
thus causing extreme sensitivity to pain (hyperalgesia) (44). While 
the expression of PE Nav1.7 mutations produces hyperexcitabil-
ity in DRG neurons, studies on cultured rat sympathetic ganglion 
neurons indicate that expression of these same PE mutations in 
sympathetic ganglion neurons, that is, another cell type in which 
Nav1.7 is normally expressed, leads to a reduction of excitability 
in these cells (43). This occurs because Nav1.8 channels, which 
are relatively resistant to inactivation by depolarization and are 
selectively expressed in addition to Nav1.7 in DRG neurons, are 
not present within sympathetic ganglion neurons (43). These PE 
mutations produce membrane depolarization due to an overlap 
between activation and steady-state inactivation, which inactivates 
sodium channels other than Nav1.8. The depolarization brings 
DRG neurons closer to the threshold of activation for the Nav1.8 
channels that are present within DRG neurons, thus increasing 
the excitability of these cells. But in sympathetic ganglion neurons, 
which lack Nav1.8, the inactivation of the sodium channels results 
in reduced excitability. Introduction of Nav1.8 allows these cells to 
fire action potentials, despite depolarization of resting membrane 
potential (43). This illustrates an important principle, that the 
phenotype associated with a monogenic channelopathy is not pre-
dictable on the basis of the changes in physiology of the mutant 
sodium channel per se. The effect depends on the cell background 
in which the mutant channel is expressed, so that physiological 
interactions that are specific to particular types of neurons (in the 
case of PE, the physiological interaction of Nav1.7 and Nav1.8) may 
better explain the symptoms experienced by patients (45). These 
data provide an explanation of why PE presents with pain due to 
Figure 4
Four clinical situations in which Nav1.7 chan-
nel activity is altered. PE and PEPD are auto-
somal dominant (AD) conditions, while CIP 
is inherited via an autosomal recessive (AR) 
trait. The mutations of the Nav1.7 channel 
grossly dictate that there is a gain of function 
(increased channel activity) in PE and PEPD, 
while Nav1.7 channel function is lost (absent) 
in CIP. The resultant phenotype is reflected in 
the lower row. In humans, the Nav1.7 muta-
tions result in pain in the feet and hands (in 
PE) or ocular, mandibular, and/or rectal pain 
(in PEPD). In CIP, there is a loss of Nav1.7 
channel function, resulting in an inability to 
register pain.
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hyperexcitability of nociceptors together with sympathetic dys-
function (flushing/erythema) that is at least in large part due to 
hypoexcitability of sympathetic ganglion neurons (43).
Paroxysmal extreme pain disorder
The condition first described in 1959 as rectal, ocular, and submax-
illary pain (46) has recently been renamed PEPD (OMIM 167400) 
(47). PEPD is an autosomal dominant disorder characterized by 
paroxysmal episodes (of sudden onset and increased intensity upon 
recurrence) of pain at different body sites, accompanied by skin 
flushing. There are four well-defined types of painful episodes. The 
first occurs at birth with an archetypical red flush spread over the 
buttocks and down the backs of the legs to the soles of the feet (48). 
A second pattern involves rectal pain that is most evident in child-
hood and typically occurs at defecation, as a sudden (short-lived) 
onset of burning pain that moves down to the lower extremities 
(47). The pain is followed by red discoloration of the skin of the 
pubic area, scrotum, perineum, buttocks, and the backs of both 
legs and soles of the feet, lasting for about an hour. The ocular pat-
tern of pain is described as an intense burning sensation, lasting 
30–60 seconds, followed by conjunctival injection (nonuniform 
redness of the conjunctiva) and erythema of the eyelids and of the 
skin in the temporal region, lasting a few minutes (49, 50). Attacks 
may be precipitated by yawning and crying but also occur sponta-
neously. Last, there is paroxysmal pain in the mandibular region 
on both sides, with associated transient erythema of the overlying 
skin, together with autonomic manifestations such as salivation, 
lacrimation (tearing), and rhinorrhoea (running nose). Symptoms 
may be induced in these subjects by the ingestion of cold drinks 
or acidic or spicy foods. Moreover, these individuals are prone to 
a strange feeling of pressure or even a cramp-like sensation in the 
nose, following exposure of the face to bright sunlight or strong 
winds. In some patients, the painful crisis may be associated with 
nonepileptic tonic seizures and cardiac asystole (50). Carbamaze-
pine, an antiepileptic drug, is effective in some patients, but high 
dosages may be needed to achieve efficacy (51). A principal target of 
anticonvulsant drugs in PEPD is most likely the sodium channels 
located in the peripheral sensory neuron (52).
A genome-wide linkage search in one large pedigree with PEPD 
led to linkage to a region of chromosome 2q24.3 (7). Haplotype 
analysis identified several recombinants, which narrowed the criti-
cal region down to 16 cM. As this region contained SCN9A, the 
investigators sequenced this gene and identified eight heterozygous 
missense mutations in eight families. All mutations were private, 
i.e., each family possessed a unique mutation. Interestingly, one 
individual was compound heterozygous for R996C and a de novo 
mutation (V1298D). This individual was more severely affected 
than his father. In another family in whom R996C was the only 
mutation identified, there was a less severe phenotype. In five fam-
ilies with typical PEPD, there were no SCN9A mutations found (7). 
These findings are consistent with the genetic heterogeneity of PE 
and suggest locus heterogeneity in PEPD.
Functional analysis of three mutations (I1461T, T1464I, and 
M1627K) that are attributed to PEPD was carried out in transfec-
tion experiments using a cell-based assay in which a mutant sodi-
um channel was introduced into cells that normally do not express 
sodium channels (7). On the basis of these experiments, these 
mutations were reported to impair inactivation of the α subunit 
of the Nav1.7 channel (Figure 4). Steady-state inactivation was only 
partial in mutant channels and had shifted toward higher volt-
ages in the context of near-normal activation. These changes are 
predicted to promote prolonged action potentials and repetitive 
neuron firing in response to provoking stimuli, such as stretching 
and exposure to cold temperatures (7). The different effects of PE 
mutations (which enhance channel activation) and PEPD muta-
tions (which impair channel inactivation) might contribute in part 
to the different symptomatology in these two disorders. In either 
case, these results are in keeping with the notion that Nav1.7 plays 
a critical role in modulation of the pain threshold.
Channelopathy-associated insensitivity to pain
In contrast with PE and PEPD, CIP (OMIM 243000) is an autoso-
mal recessive disorder (8, 53). Individuals with congenital indiffer-
ence to pain have painless injuries beginning in infancy but other-
wise normal sensory responses upon examination. Perception of 
passive movement, joint position, and vibration is normal, as are 
tactile thresholds and light touch perception. There is intact ability 
to distinguish between sharp and dull stimuli and to detect differ-
ences in temperature. The insensitivity to pain does not appear to 
be due to axonal degeneration, as the nerves appear to be normal 
upon gross examination (8). The complications of the disease fol-
low the inability to feel pain, and most individuals will have inju-
ries to lip or tongue caused by biting themselves in the first 4 years 
of life. Patients have frequent bruises and cuts, usually have a his-
tory of fractures that go unnoticed, and are often only diagnosed 
because of limping or lack of use of a limb. The literature contains 
very colorful descriptions of patients with congenital inability to 
perceive any form of pain. Individuals have been reported to walk 
over burning coals and to place knives through their arms and drive 
spikes through a hand as part of crucifixion reenactment (8).
Cox et al. described 6 patients stemming from three consanguin-
eous families of northern Pakistani origin (8). The highly inbred 
population allowed for autozygosity mapping (homozygosity in 
which the two alleles are identical by descent), and a genome-wide 
search led to the identification of a 20-cM homozygous region on 
chromosome 2q24.3 with a maximum 2-point lod score of 3.2 (a 
lod score of 3 or more is generally taken to indicate that 2 gene loci 
are close to each other on the chromosome; a lod score of 3 means 
the odds are a thousand to one in favor of genetic linkage). Further 
refinement of the region to 11.7 Mb was facilitated by addition of 
a third family. A bioinformatics approach suggested SCN9A as the 
best candidate disease gene. Sequencing led to the identification of 
different homozygous mutations of SCN9A, and each family pos-
sessed a unique mutation. The mutations were identified in exon 
10 (S459X), exon 13 (I767X), and exon 15 (W897X) (8). All muta-
tions are nonsense mutations, that is, they change a codon that 
codes for one amino acid into a codon that does not specify any 
amino acid. These results were confirmed by two studies: one study 
in 9 western European and North and South American families 
(54) and another in a large Canadian family (55). Both studies used 
linkage analysis, searched for homozygous haplotypes, identified 
the same gene, and detected 10 truncating SCN9A mutations. The 
majority of affected patients were homozygous for SCN9A muta-
tions, but 2 patients were compound heterozygous for different 
SCN9A mutations (54). Functional studies show that CIP-associ-
ated mutations cause loss of function of Nav1.7 (8, 55) (Figure 4). 
This is in contrast with the genetic basis of PE and PEPD, in which 
the disorders result from gain-of-function mutations. In DRG 
neurons expressing mutant Nav1.7, the firing of action potentials 
was greatly impaired and comparable to background (8).
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Implications and questions
Collectively, the data from recent studies indicate that Nav1.7 
function is an essential and nonredundant requirement for noci-
ception in humans. However, the genetic findings do not fully 
explain the clinical presentations described. Given the widespread 
expression of Nav1.7 throughout the sensory nervous system, it is 
remarkable that PE and PEPD have such different tissue distri-
butions of pain. Moreover, the variability in age of clinical onset 
remains unexplained. Also, although physiological studies have 
revealed a temperature-dependent shift that brings the activation 
threshold of PE mutant channels close to that of wild-type Nav1.7 
channels, possibly contributing to the alleviation of pain by cool-
ing in PE (56), the paroxysmal nature of the painful attacks in 
PE and PEPD is not fully understood. These observations argue 
that there may be factors other than the mutated Nav1.7 channel, 
such as still–to be–identified binding partners (other protein mol-
ecules that the channel interacts with, such as fibroblast growth 
factor homologous factors, which are known to modulate the 
physiological properties of the sodium-channel isoforms) that are 
important in determining the topographic and temporal pattern 
of these symptoms (57, 58).
The important role of mutations that change the sequence of 
SCN9A in various pain disorders suggests that SCN9A polymor-
phisms might contribute to intersubject variability in the sensation 
of pain in humans. This should encourage researchers to look for 
SCN9A polymorphisms that are associated with chronic pain disor-
ders other than PE and PEPD. It might also be expected that some 
SCN9A polymorphisms might confer protection against pain.
Implications for new therapeutic approaches to pain
Neuropathic pain in PE is therapeutically challenging (59). Indeed, 
Nav1.7 represents a target that might be inhibited by small mole-
cules in a subtype-specific or state-dependent manner during ecto-
pic discharge, producing pain relief while sparing other neuronal 
functions. The development of subtype selectivity of potentially 
therapeutically useful molecules has proven to be a challenge. Sev-
eral classes of drugs, including local anesthetics (e.g., lidocaine), 
systemic antiarrhythmics (e.g., mexiletine), and antiepileptic drugs 
such as phenytoin or carbamazepine, target sodium channels and 
act as channel blockers, although they do not show a high degree 
of channel subtype specificity and thus inhibit many types of 
sodium channels rather than selectively blocking Nav1.7 (52, 58). 
These agents, which act primarily through use-dependent blocks 
of sodium channels indeed are part of the armamentarium for the 
treatment of many types of chronic pain, including some forms of 
neuropathic pain. Several of these drugs have shown a degree of 
efficacy in patients with pain due to mutations in Nav1.7. Some 
PE patients have responded to oral mexiletine (600 mg daily) (60). 
Interestingly, some PE mutations attenuate the inhibitory effect 
on sodium channels of the sodium-channel blocker lidocaine, 
while other PE mutations do not, suggesting that the response to 
treatment with sodium-channel blockers in PE may depend on the 
specific genotype (61). Carbamazepine is effective in some patients 
with PEPD, as it stabilizes the inactivated state of sodium channels, 
meaning that fewer of these channels are available to open, mak-
ing brain cells less excitable (7). In contrast, preliminary results in 
PE indicate low or absent effectivity of this drug (62). Moreover, in 
those cases in which lidocaine or mexiletine are helpful in PE, the 
efficacy of these agents is only partial or transient (63).
In conclusion, these observations, while drawn from a small 
number of patients, suggest that blockade of voltage-gated sodi-
um channels is a promising therapeutic option for the treatment 
of pain but emphasize the need for the design of more highly 
focused, Nav1.7-specific blockers or genetically tailored pharma-
cological options for future testing. There will undoubtedly be 
progress along these lines in the future.
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